Acoramidis Reduces ATTR-CM Mortality & Hospitalization. 02/12/26
Welcome to Cardiology Today â Recorded February 12, 2026. This episode summarizes 5 key cardiology studies on topics like transthyretin silencers and macrophage PRMT9. Key takeaway: Acoramidis Reduces ATTR-CM Mortality & Hospitalization..
Article Links:
Article 1: Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). (Journal of the American College of Cardiology)
Article 2: Myocardial Amyloid Burden in Transthyretin Amyloidosis. (Journal of the American College of Cardiology)
Article 3: Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. (Journal of the American College of Cardiology)
Article 4: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. (Journal of the American College of Cardiology)
Article 5: Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1. (Circulation)
Full episode page: https://podcast.explainheart.com/podcast/acoramidis-reduces-attr-cm-mortality-hospitalization-02-12-26/
đ Featured Articles
Article 1: Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II).
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41670556
Summary: The novel thin-strut sirolimus-eluting iron bioresorbable scaffold demonstrated safety and efficacy in a prior nonrandomized first-in-human study. The IRONMAN-II trial, a prospective multicenter randomized study, directly compared this bioresorbable scaffold with contemporary metallic cobalt chromium everolimus-eluting stents. This head-to-head comparison addressed the clinical need for advanced percutaneous coronary intervention devices in patients with coronary artery disease.
Article 2: Myocardial Amyloid Burden in Transthyretin Amyloidosis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41369616
Summary: Cardiovascular magnetic resonance extracellular volume reflects myocardial amyloid, establishing its role as a quantitative measure. This characteristic means it provides a framework for disease staging and therapeutic planning in transthyretin amyloidosis. The study confirmed the utility of defining calibrated thresholds and evaluating the diagnostic and prognostic value of this noninvasive measure.
Article 3: Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41225306
Summary: Therapies for transthyretin amyloidosis with cardiomyopathy, including transthyretin stabilizers and silencers, demonstrated a clear mortality benefit in three previous randomized trials. The current study rigorously evaluated the time course of this mortality benefit, which had often appeared delayed. Understanding this precise time course provides critical information for optimizing clinical use and guiding future trial design.
Article 4: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM.
Journal: Journal of the American College of Cardiology
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41143759
Summary: Acoramidis, an approved oral therapy for transthyretin amyloid cardiomyopathy, achieves early and near-complete (90 percent) transthyretin stabilization. In the phase three ATTRibute-CM study, acoramidis significantly reduced the composite endpoint of all-cause mortality or first cardiovascular-related hospitalization. This finding demonstrates acoramidis’s effectiveness in improving recurrent and cumulative outcomes for patients with transthyretin amyloid cardiomyopathy.
Article 5: Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41669821
Summary: Macrophage PRMT9 ameliorates acute myocardial infarction by promoting symmetric dimethylation and degradation of STAT1 protein. This mechanism directly modulates M1-like macrophages, which are known to exacerbate myocardial injury through excessive secretion of inflammatory cytokines during myocardial infarction. The finding establishes PRMT9 as a novel and specific therapeutic target for acute myocardial infarction.
đ Transcript
Today’s date is February 12, 2026. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Sirolimus-Eluting Iron Bioresorbable Scaffolds vs Everolimus-Eluting Stents for Percutaneous Coronary Intervention: A Randomized Trial (IRONMAN II). The novel thin-strut sirolimus-eluting iron bioresorbable scaffold demonstrated safety and efficacy in a prior nonrandomized first-in-human study. The IRONMAN-II trial, a prospective multicenter randomized study, directly compared this bioresorbable scaffold with contemporary metallic cobalt chromium everolimus-eluting stents. This head-to-head comparison addressed the clinical need for advanced percutaneous coronary intervention devices in patients with coronary artery disease.
Article number two. Myocardial Amyloid Burden in Transthyretin Amyloidosis. Cardiovascular magnetic resonance extracellular volume reflects myocardial amyloid, establishing its role as a quantitative measure. This characteristic means it provides a framework for disease staging and therapeutic planning in transthyretin amyloidosis. The study confirmed the utility of defining calibrated thresholds and evaluating the diagnostic and prognostic value of this noninvasive measure.
Article number three. Timing of Mortality Benefit in Outcomes Trials in Transthyretin Amyloidosis. Therapies for transthyretin amyloidosis with cardiomyopathy, including transthyretin stabilizers and silencers, demonstrated a clear mortality benefit in three previous randomized trials. The current study rigorously evaluated the time course of this mortality benefit, which had often appeared delayed. Understanding this precise time course provides critical information for optimizing clinical use and guiding future trial design.
Article number four. Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis From ATTRibute-CM. Acoramidis, an approved oral therapy for transthyretin amyloid cardiomyopathy, achieves early and near-complete (90 percent) transthyretin stabilization. In the phase three ATTRibute-CM study, acoramidis significantly reduced the composite endpoint of all-cause mortality or first cardiovascular-related hospitalization. This finding demonstrates acoramidis’s effectiveness in improving recurrent and cumulative outcomes for patients with transthyretin amyloid cardiomyopathy.
Article number five. Macrophage PRMT9 Ameliorates Acute Myocardial Infarction by Promoting Symmetric Dimethylation and Degradation of STAT1. Macrophage PRMT9 ameliorates acute myocardial infarction by promoting symmetric dimethylation and degradation of STAT1 protein. This mechanism directly modulates M1-like macrophages, which are known to exacerbate myocardial injury through excessive secretion of inflammatory cytokines during myocardial infarction. The finding establishes PRMT9 as a novel and specific therapeutic target for acute myocardial infarction.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
transthyretin silencers, macrophage PRMT9, percutaneous coronary intervention, cardiovascular outcomes, M1-like macrophages, transthyretin amyloidosis, time-varying treatment effects, myocardial amyloid burden, transthyretin amyloidosis with cardiomyopathy, transthyretin stabilizers, coronary artery disease, everolimus-eluting stent, IRONMAN two trial, sirolimus-eluting iron bioresorbable scaffold, diagnostic value, symmetric dimethylation, all-cause mortality, transthyretin amyloid cardiomyopathy, cardiovascular magnetic resonance, TTR stabilization, extracellular volume, STAT1 degradation, acoramidis, acute myocardial infarction, mortality benefit.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow